[Cutaneous side effects of antiangiogenic agents].
Antiangiogenic agents can be associated with cutaneous side effects with a new and original spectrum of skin symptoms. A correlation between the molecular targets and skin manifestations is proposed. Further prospective studies are necessary in order to evaluate the potential association between skin side effects and clinical response. Systematic report and characterization of side effects occurring with new targeted therapies is critical. It will help us understanding better skin pathophysiology, but, most of all, it will lead to more efficient symptomatic treatment for our patients.
Robert
Caroline
C
Service de dermatologie, Institut Gustave Roussy, 39, rue Camille-Desmoulins, 94800 Villejuif. caroline.robert@igr.fr
D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates / Q000009:adverse effects*; D000068258:Bevacizumab; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D007211:Indoles / Q000009:adverse effects*; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D010859:Pigmentation Disorders / Q000139:chemically induced; D011725:Pyridines / Q000009:adverse effects*; D011758:Pyrroles / Q000009:adverse effects*; D012871:Skin Diseases / Q000139:chemically induced*; D000077157:Sorafenib; D000077210:Sunitinib
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001557:Benzenesulfonates; D007211:Indoles; D010671:Phenylurea Compounds; D011725:Pyridines; D011758:Pyrroles; D009536:Niacinamide; D000068258:Bevacizumab; D000077157:Sorafenib; D000077210:Sunitinib